Contrast Media pp 207-217 | Cite as

Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Media

  • Henrik S. Thomsen
Part of the Medical Radiology book series (MEDRAD)


Nephrogenic systemic fibrosis (NSF) is an adverse reaction to gadolinium, which is toxic in its free, unchelated form. NSF is seen after the least stable gadolinium-based contrast agents in patients with reduced renal kidney function or on dialysis. The introduction of guidelines has led to a reduction in the incidence of NSF, but it is too soon to state that it has been totally eliminated. The long-term effects of retention of gadolinium in the body require further investigation.


Chronic Kidney Disease Normal Renal Function Nephrogenic Systemic Fibrosis Gadopentetate Dimeglumine Poor Renal Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abraham JL, Thakral C (2008) Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 66:200–207CrossRefPubMedGoogle Scholar
  2. Abraham JL, Thakral C, Skov L et al (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273–280CrossRefPubMedGoogle Scholar
  3. ACR Committee on Drugs and Contrast Media (2012) ACR manual on contrast media version 8.0. ISBN: 978-1-55903-009-0Google Scholar
  4. Amet S, Choukroun G, Launay-Vacher V et al (2012) Prevalence of nephrogenic systemtic fibrosis in dialysis patients: the Pro-FINEST study. ECR 2012 Book of Abstracts. Insights Imaging 3(Suppl 1):S293Google Scholar
  5. Band RA, Gaieski DF, Mills AM et al (2007) Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast induced nephropathy. Am J Emerg Med 25:268–272CrossRefPubMedGoogle Scholar
  6. Bennett CL, Qureshi ZP, Sator OA et al (2012a) Gadolinium induced nephrogenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J 5:82–88PubMedCentralCrossRefPubMedGoogle Scholar
  7. Bennett CL, Starko KM, Thomsen HS et al (2012b) Linking drugs to obscure illness: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. A report from the Southern Network on adverse reactions (SONAR). J Gen Intern Med 27:1697–1703PubMedCentralCrossRefPubMedGoogle Scholar
  8. Blaufox MD, Aurell M, Bubeck B et al (1996) Report of the Radionuclide in Nephrourology Committee on renal clearance. J Nucl Med 37:1883–1890PubMedGoogle Scholar
  9. Bostom AG, Kronenberg F, Ritz E (2002) Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13:2140–2144CrossRefPubMedGoogle Scholar
  10. Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 6:230–234CrossRefGoogle Scholar
  11. Center for Disease Control and Prevention (CDC) (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents, St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 56:137–141Google Scholar
  12. Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefGoogle Scholar
  13. Collidge T, Thomson P, Mark P et al (2010) Is this really a true case of NSF following Gadovist exposure alone? Nephrol Dial Transpl 24:1352–1353 (Note: this ref has been moved up)Google Scholar
  14. Commission Decision of 1.7.2010 concerning, in the framework of Article 31 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations for Gadolinium-containing contrast agents for human use which contain one or more of the active substances “gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid”. Accessed Dec 2011
  15. Cowper SE (2007) Nephrogenic systemic fibrosis. Adv Dermatol 23:131–154CrossRefPubMedGoogle Scholar
  16. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous disease in renal dialysis patients. Lancet 356:1000–1001CrossRefPubMedGoogle Scholar
  17. Cowper SE, Rabach M, Girardi M (2008) Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66:200–207CrossRefGoogle Scholar
  18. Diego DR (2008) Nephrogenic system fibrosis: a radiologist’s practical perspective. Eur J Radiol 66:220–224CrossRefGoogle Scholar
  19. Edward M, Quinn JA, Mukherjee S (2008) Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214:584–593CrossRefPubMedGoogle Scholar
  20. Eken C, Kilicaslan I (2007) Differences between various glomerular filtration rate calculation methods in predicting patients at risk for contrast-induced nephropathy. Am J Emerg Med 25:487 (Correspondence)Google Scholar
  21. Elmholdt TR, Jørgensen B, Ramsing M et al (2010) Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 3:285–287CrossRefGoogle Scholar
  22. European Medicines Agency (2007) Public assessment report, 26th June 2007. Accessed 22 July 2008
  23. Evans CH (1990) Biochemistry of the lanthanides. Plenum Press, New YorkCrossRefGoogle Scholar
  24. Evans CH, Drouven BJ (1983) The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J 213:751–758PubMedGoogle Scholar
  25. Food and Drug Administration (2011) Press release September 9th 2010 Accessed 1st Oct 2010, Dec 2011
  26. Frenzel T, Lengsfeld P, Schirmer H et al (2008) Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 37 °C. Invest Radiol 43:817–828CrossRefPubMedGoogle Scholar
  27. Girardi M, Kay J, Elston DM (2011) Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 65:1095–1106CrossRefPubMedGoogle Scholar
  28. Grobner T (2006) Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl 21:1104–1108CrossRefGoogle Scholar
  29. Haylor J, Dencausse A, Vickers M et al (2012) Skin gadolinium following MRI contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 263:107–116CrossRefPubMedGoogle Scholar
  30. High W, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:27–30CrossRefGoogle Scholar
  31. Janus N, Launay-Vacher V, Karie S et al (2010) Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 73(2):357–359CrossRefPubMedGoogle Scholar
  32. Kalb RE, Helm TN, Sperry H et al (2008) Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 8:607–610Google Scholar
  33. Kanal E, Barkovich AJ, Bell C et al (2007) ACR blue ribbon panel on MR safety. ACR guidance document for safe MR practices: 2007. Am J Roentgenol 188:1447–1474CrossRefGoogle Scholar
  34. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470CrossRefPubMedGoogle Scholar
  35. Levey AS, Greene T, Kusek J, Beck GA (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:155Google Scholar
  36. Levey AS, Coresh J, Greene T et al, Chronic Kidney Disease Epidemiology Collaboration (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772Google Scholar
  37. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMedCentralCrossRefPubMedGoogle Scholar
  38. MacNeil S, Bains S, Johnson C et al (2011) Gadolinium contrast agent associated stimulation of human fibroblast collagen production. Invest Radiol 46:711–717PubMedGoogle Scholar
  39. Marckmann P (2008) An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol 66(2):187–190CrossRefPubMedGoogle Scholar
  40. Marckmann P, Skov L, Rossen K et al (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transpl 22:3174–3178CrossRefGoogle Scholar
  41. Marckmann P, Skov L, Rossen K, Thomsen HS (2008) Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 69:161–168CrossRefPubMedGoogle Scholar
  42. Maton F, van der Elst L, Muller RN (1995) Influence of human proteins on the relaxivity of Gd(III) complexes. Accessed 4/6/2012
  43. Michels WM, Grootendorst DC, Verduijn M et al (2010) Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5:1003–1009CrossRefPubMedGoogle Scholar
  44. Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73–76CrossRefPubMedGoogle Scholar
  45. Morcos SK, Thomsen HS, Webb JAW, Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) (2002) Dialysis and contrast media. Eur Radiol 12:3026–3030Google Scholar
  46. Müller N, Günzel P, Schöbel C (1992) Ionic and non-ionic gadolinium-containing magnetic resonance contrast media. Comparison of effects and their reversibility in repeated dose toxicity studies in rats. Adv MRI Contrast 1(Suppl 1):15–28Google Scholar
  47. Parazella MA (2007) Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2:200–2002CrossRefGoogle Scholar
  48. Pirovano G, Munley J, Schultz C et al (2012) Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. ECR 2012 Book of Abstracts. Insights Imaging 3(Suppl 1):S293Google Scholar
  49. Reilly PF (2008) Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3:747–751CrossRefPubMedGoogle Scholar
  50. Rosky NM, Sherry AD, Lenkinski RE (2008) Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247:608–612CrossRefGoogle Scholar
  51. Rydahl C, Thomsen HS, Marckman P (2008) High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a Gadolinium(Gd)- containing magnetic resonance contrast agent. Invest Radiol 43:141–144CrossRefPubMedGoogle Scholar
  52. Sieber MA, Pietsch H, Walter J et al (2008a) A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium based contrast media. Invest Radiol 43:65–75CrossRefPubMedGoogle Scholar
  53. Sieber MA, Lengsfeld P, Walter J et al (2008b) Gadolinium based contrast agents and their potential role in the patho- genesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 27:955–962CrossRefPubMedGoogle Scholar
  54. SMRM workshop on contrast enhanced magnetic resonance (1991) Discussion. Magn Reson Med 22:229–232CrossRefGoogle Scholar
  55. Stenver DI (2008) Pharmacovigilance: what to do if you see an adverse reaction and the consequences. Eur J Radiol 66:184–186CrossRefPubMedGoogle Scholar
  56. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483CrossRefPubMedGoogle Scholar
  57. Swaminathan S, High WA, Ranville et al (2008) Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73:1413–1418CrossRefPubMedGoogle Scholar
  58. Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16:2619–2621PubMedCentralCrossRefPubMedGoogle Scholar
  59. Thomsen HS (2007) ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17:2692–2696CrossRefPubMedGoogle Scholar
  60. Thomsen HS (2010) Contrast-enhanced MRI in patients with impaired renal function: recent recommendations to minimize the risk of nephrogenic systemic fibrosis. Solut Contrast Imaging 1(2):1–8Google Scholar
  61. Thomsen HS, Bennett CL (2012) Six years after. Acta Radiol 53:827–829CrossRefPubMedGoogle Scholar
  62. Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) In which patients should serum-creatinine be measured before contrast medium administration? Eur Radiol 15:749–754Google Scholar
  63. Thomsen HS, Marckmann P (2008) Extracellular Gd-CA: differences in prevalences of NSF. Eur J Radiol 66:180–183CrossRefPubMedGoogle Scholar
  64. Thomsen HS, Marckmann P, Logager VB (2007a) Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imag 7:130–137CrossRefGoogle Scholar
  65. Thomsen HS, Marckmann P, Logager VB (2007b) Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 48:593–596CrossRefPubMedGoogle Scholar
  66. Thomsen HS, Morcos SK, Almén T, Bellin M-F, Bertolotto M, Bongartz G, Clement O, Leander P, Heinz-Peer G, Reimer P, Stacul F, van der Molen A, Webb JAW (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 23:307–318CrossRefPubMedGoogle Scholar
  67. Todd DJ, Kagan A, Chibnik LB, Kay J (2007) Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheumat 56:3433–3441CrossRefPubMedGoogle Scholar
  68. Tweedle MF, Gaughan GT, Hagan J et al (1988) Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. Nucl Med Biol, Int J Radiat Appl Instrum Part B 15:31–36Google Scholar
  69. Tweedle MF, Wedeking P, Kumar K (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30:372–380CrossRefPubMedGoogle Scholar
  70. Wadas TJ, Sherman CD, Minor JH et al (2010) The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 64:1274–1280PubMedCentralCrossRefPubMedGoogle Scholar
  71. Wertman R, Altun E, Martin DR (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248:799–806CrossRefPubMedGoogle Scholar
  72. White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd (DTPA-BMA) (Omniscan) versus GD (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41:272–278CrossRefPubMedGoogle Scholar
  73. Wollanka H, Weidenmaier W, Giersig C (2009) NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transpl 24:3882–3884CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Diagnostic RadiologyCopenhagen University Hospital HerlevHerlevDenmark

Personalised recommendations